Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.13
AMRS's Cash to Debt is ranked lower than
53% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. AMRS: 0.13 )
AMRS' s 10-Year Cash to Debt Range
Min: 0.1   Max: No Debt
Current: 0.13

Equity to Asset -0.68
AMRS's Equity to Asset is ranked lower than
51% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. AMRS: -0.68 )
AMRS' s 10-Year Equity to Asset Range
Min: -0.93   Max: 0.87
Current: -0.68

-0.93
0.87
F-Score: 2
Z-Score: -9.19
M-Score: -2.56
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Revenue Growth (%) -53.60
AMRS's Revenue Growth (%) is ranked lower than
97% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. AMRS: -53.60 )
AMRS' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -53.6
Current: -53.6

EBITDA Growth (%) -17.70
AMRS's EBITDA Growth (%) is ranked lower than
96% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. AMRS: -17.70 )
AMRS' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -17.7
Current: -17.7

EPS Growth (%) -28.00
AMRS's EPS Growth (%) is ranked lower than
93% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. AMRS: -28.00 )
AMRS' s 10-Year EPS Growth (%) Range
Min: 0   Max: -28
Current: -28

» AMRS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2012

AMRS Guru Trades in Q4 2012

Paul Tudor Jones 20,600 sh (New)
» More
Q1 2013

AMRS Guru Trades in Q1 2013

Paul Tudor Jones 11,600 sh (-43.69%)
» More
Q2 2013

AMRS Guru Trades in Q2 2013

Paul Tudor Jones 11,600 sh (unchged)
» More
Q3 2013

AMRS Guru Trades in Q3 2013

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AMRS



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Amyris, Inc.

Billionaires Hold Waning Biotechs 42% Off
Year 2013 has been called the year of the biotech return. According to BioTechNow, the sector is doing better than it has since 2007. One of the highlighted companies today, StemCells Inc. (STEM) just completed its successful IPO last week. Read more...

Ratios

vs
industry
vs
history
P/S 6.11
AMRS's P/S is ranked higher than
69% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 10.38 vs. AMRS: 6.11 )
AMRS' s 10-Year P/S Range
Min: 0.52   Max: 9.69
Current: 6.11

0.52
9.69
EV-to-EBIT -2.58
AMRS's EV-to-EBIT is ranked lower than
51% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. AMRS: -2.58 )
AMRS' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -2.58

Valuation & Return

vs
industry
vs
history

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:3A0.Germany
Amyris, Inc., was formed as a California corporation in 2003 under the name Amyris Biotechnologies, Inc. The Company is a renewable products company. It provides alternatives to petroleum-sourced products used in transportation fuel markets and specialty chemical. The Company uses its proprietary synthetic biology platform to design microbes, primarily yeast, and use them as living factories in established fermentation processes to convert plant-sourced sugars into renewable hydrocarbons. The Company develops and commercializes products from these hydrocarbons in markets, including cosmetics, lubricants, flavors and fragrances, polymers and plastic additives, home and personal care products and transportation fuels. The Company develops technology capable of creating microbial strains to produce artemisinic acid - a precursor of artemisinin, an effective anti-malarial drug. It granted a royalty-free license to this technology to Sanofi-Aventis, which currently expects to begin distributing artemisinin-based anti-malarial drugs made through its technology in 2013. Its production operations involve two steps. First, the company produces the target molecule by means of an industrial fermentation process. In certain cases this target molecule is itself the desired end product. In other cases, target molecule must be converted into the desired end product by means of chemical finishing steps where the company uses chemical synthesis of the initial target molecule to produce a final target molecule. It has two operating subsidiaries, Amyris Brasil Ltda., and Amyris Fuels, LLC,. Amyris Brasil oversees the establishment and expansion of Amyris's production in Brazil, and Amyris Fuels was established to help the Company develop fuel distribution capabilities in the United States. The Company competes with both the traditional, largely petroleum-based specialty chemical and fuels products that are used in markets. The Company is subject to a variety of federal, state, local and international laws, regulations and permit requirements governing the use, generation, manufacture, transportation, storage, handling and disposal of these materials in the U.S., Brazil and other countries.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide